Drugs for disorders of the nervous system

Introduced: January 2000

Last revised: January 2006

Classification Context

Section:: HUMAN NECESSITIES
Class:: MEDICAL OR VETERINARY SCIENCE; HYGIENE
Subclass:: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Filing statistics

IPC A61P 25/00 belongs to the parent subclass A61P, which recorded 1,178,026 patent applications worldwide between 2013 and 2023. Annual filings grew from 87,753 in 2013 to 99,310 in 2023 (+13%), peaking at 118,515 applications in 2021. The most active applicants in class A61 are PHILIPS ELECTRONICS (18,523 applications), NOVARTIS (14,253 applications) and COVIDIEN (13,953 applications).

Source: EPO PATSTAT, worldwide filings

12 direct subcodes

Child Classifications

Navigate with arrow keys, Enter to open

A61P 25/02 for peripheral neuropathies
A61P 25/04 Centrally acting analgesics, e.g. opioids
A61P 25/06 Antimigraine agents
A61P 25/08 Antiepileptics; Anticonvulsants
A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A61P 25/2 Hypnotics; Sedatives
A61P 25/22 Anxiolytics
A61P 25/24 Antidepressants
A61P 25/26 Psychostimulants, e.g. nicotine, cocaine
A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/3 for treating abuse or dependence

Top Applicants

Top 10 applicants by patent filingsfor class A61, 2013–2023, worldwide · Source: EPO PATSTAT

PHILIPS ELECTRONICS NL 18,523
NOVARTIS CH 14,253
COVIDIEN US 13,953
ROCHE CH 12,005
CHINESE ACADEMY OF SCIENCES 11,955
UNIVERSITY OF CALIFORNIA US 11,692
HARVARD UNIVERSITY US 11,596
L'OREAL FR 11,593
P&G (PROCTER & GAMBLE COMPANY) US 11,297
OLYMPUS CORPORATION JP 9,594